Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Sell
81,237
-26,519
-25% -$706K 0.03% 392
2025
Q4
$2.68M Buy
107,756
+28,693
+36% +$724K 0.03% 375
2025
Q3
$1.95M Buy
79,063
+6,052
+8% +$149K 0.03% 403
2025
Q2
$1.77M Sell
73,011
-32,603
-31% -$760K 0.03% 409
2025
Q1
$2.68M Buy
105,614
+100
+0.1% +$2.62K 0.05% 292
2024
Q4
$2.8M Sell
105,514
-11,743
-10% -$319K 0.05% 291
2024
Q3
$3.39M Buy
117,257
+20,639
+21% +$602K 0.06% 268
2024
Q2
$2.7M Buy
96,618
+1,384
+1% +$38.1K 0.06% 271
2024
Q1
$2.64M Buy
95,234
+30,760
+48% +$854K 0.06% 278
2023
Q4
$1.86M Sell
64,474
-24,229
-27% -$732K 0.05% 309
2023
Q3
$2.94M Sell
88,703
-1,120
-1% -$39.6K 0.09% 187
2023
Q2
$3.29M Sell
89,823
-74,107
-45% -$2.88M 0.11% 177
2023
Q1
$6.69M Sell
163,930
-349,271
-68% -$15.1M 0.25% 98
2022
Q4
$26.3M Buy
513,201
+30,896
+6% +$1.48M 1.13% 14
2022
Q3
$21.1M Buy
482,305
+45,950
+11% +$2.23M 1% 22
2022
Q2
$22.9M Buy
436,355
+74,360
+21% +$3.79M 1.04% 17
2022
Q1
$18.7M Buy
361,995
+233,184
+181% +$12.1M 0.83% 27
2021
Q4
$7.61M Buy
128,811
+50,611
+65% +$2.51M 0.32% 82
2021
Q3
$3.36M Buy
78,200
+71,440
+1,057% +$3.16M 0.2% 98
2021
Q2
$265K Buy
+6,760
New +$263K 0.02% 252

Other funds holding PFE

NewEdge Wealth's PFE Position: Q1 2026 in Review

NewEdge Wealth reduced its Pfizer (PFE) stake by 25% in Q1 2026, selling an estimated $706K and leaving 81,237 shares worth $2.28M. The position accounts for 0.03% of the portfolio, ranked #392.

NewEdge Wealth first reported a position in PFE in Q2 2021 and has held it in 20 quarters since. The position peaked at $26.3M in Q4 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • NewEdge Wealth held 81,237 shares of Pfizer worth $2.28M as of Q1 2026.
  • NewEdge Wealth sold 26,519 Pfizer shares in Q1 2026, an estimated $706K.
  • Pfizer made up 0.03% of NewEdge Wealth's portfolio in Q1 2026, its #392 holding.
  • NewEdge Wealth first reported a position in Pfizer in Q2 2021 and has held it in 20 quarters since.
  • NewEdge Wealth's Pfizer position peaked at $26.3M in Q4 2022.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.